Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

LIGAND PHARMACEUTICALS INC (LGND)

$300.53 -0.54% NASDAQ: LGND · 15-min delayed
  • SAN DIEGO, California
  • Public · NASDAQ: LGND
  • 47 employees
$4.7BMarket cap
$268.1MRevenue · FY2025
$124.5MNet income
47Employees
LGNDNASDAQ
1994IPO

About LIGAND PHARMACEUTICALS INC

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$268.1M
Net income
$124.5M
Total assets
$1.6B
Market cap
$4.7B
Operating margin
15.3%
Net margin
46.4%

Source: SEC EDGAR · updated Jun 8, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$268.1M
Operating expenses
$227.1M
Operating income
$41.0M
Income tax
$34.5M
Net income
$124.5M
EPS (basic)
$6.44
EPS (diluted)
$6.13

Balance sheet

Total assets
$1.6B
Current assets
$832.3M
Total liabilities
$543.4M
Current liabilities
$37.4M
Shareholders’ equity
$1.0B

Cash flow

Operating cash flow
$49.4M
Investing cash flow
-$377.3M
Financing cash flow
$428.2M
Net cash flow
$102.6M

Statements via Polygon.io (SEC filings)

NASDAQ: LGND
$300.53 -0.54%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$112.56 $322.61

52-week range

Market cap
$4.7B
P/E ratio
49.0
EPS (diluted)
$6.13
Shares outstanding
15.8M
Open
Day range
Prev close
Volume
IPO date
Nov 25, 1994

Ligand Pharmaceuticals Inc (LGND) Stock Price

  • Profitable — net income of $124.5M in FY2025.
  • Revenue declined 3% from FY2021 to FY2025.
  • Trading 7% below its 52-week high.
  • Valued at a price-to-earnings (P/E) ratio of 49.0.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review LIGAND PHARMACEUTICALS INC.

Write a review
Newsroom

News about LIGAND PHARMACEUTICALS INC

News & sentiment via Polygon.io

FAQ

Ligand Pharmaceuticals Inc: frequently asked questions

Is Ligand Pharmaceuticals Inc an American company?

Ligand Pharmaceuticals Inc is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Ligand Pharmaceuticals Inc headquartered?

Ligand Pharmaceuticals Inc is headquartered in San Diego, California, United States.

Is Ligand Pharmaceuticals Inc publicly traded?

Yes — Ligand Pharmaceuticals Inc is a publicly traded company. Its stock trades under the ticker symbol LGND on the NASDAQ.

What does Ligand Pharmaceuticals Inc do?

Ligand Pharmaceuticals Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →